References
- Castro J. E., Griffiths H. J. L., Schackman R. Significance of signs and symptoms in benign prostatic hypertrophy. Brit. Med. J. 1969; 2: 598
- Clarke R. The prostate and the endocrines. Brit. J. Urol. 1937; 9: 254
- Geller J., Bora R., Roberts Th., Newman H., Lin A., Silva R. Treatment of benign prostatic hypertrophy with hydroxyprogeste-rone caproate: Effect on clinical symptoms, morphology and endocrine function. J. Amer. med. Ass. 1965; 193: 121
- Geller J., Fruchtman B., Meyers C., Newman H. Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate. J. Clin. Endocrin. 1967; 27: 556
- Geller J., Angrist A., Nakoa K., Newman H. Therapy with progestational agents in advanced benign prostatic hypertrophy. J. Amer. med. Ass. 1969; 210: 1421
- Hahn J. D., Neumann F., von Berswordt-Wallrabe R. Tierexperimentelle Unter-suchungen mit 19-nor-17-α-hydroxy-progeste-ron-capronat (Gestenoroncapronat) im Hinblick auf eine mögliche therapeutische Anwendung beim Prostataadenom. Urologie 1968; 7: 208
- Kaufmann J. Untersuchungen zur kausalen Genese der Prostatahypertrophie. II Teil. Z. Urol. 1968; 61: 229
- Lebech P. E., Nordentoft E. L. A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol acetate. Acta Obstet. Gynec. Scand. 1967; 46: 25, suppl. 9
- Lund F. Problems of prostatic hypertrophy in a geriatric department. Nord. Med. 1959; 62: 1784
- Rangno R. E., McLeod P. J., Ruedy J., Ogilvie R. I. Treatment of benign prostatic hypertrophy with medrogestone. Clin. Pharm. Ther. 1971; 12: 658
- Scott W. W., Wade J. C. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J. Urol. 1969; 101: 81
- Vahlensieck W., Gödde S. Behandlung der Prostatahypertrophie mit Gestagenen. Münch. Med. Wschr. 1968; 110: 1573
- Wolf H., Madsen P. O. Treatment of benign prostatic hypertrophy with progestational agent: a preliminary report. J. Urol. 1968; 99: 780